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Abstract
Background According to a recent consensus, the cachectic
syndrome is defined as: “… a complex metabolic syndrome
associated with underlying illness and characterized by loss
of muscle with or without loss of fat mass. The prominent
clinical feature of cachexia is weight loss in adults
(corrected for fluid retention) or growth failure in children
(excluding endocrine disorders). Anorexia, inflammation,
insulin resistance, and increased muscle protein breakdown
are frequently associated with cachexia.” Although this
definition is accompanied by diagnostic criteria, it does not
consider the problem of staging. Stratification of patients is
important when considering therapy. The very first stage of
the wasting syndrome does not necessarily involve body
weight loss—a state known as pre-cachexia.
Methods and Results The aim of the present score was to
overcome the problem of patient staging in cancer. This
score considers five main different factors: body weight and
lean body mass loss; anorexia; inflammatory, immunolog-
ical, and metabolic disturbances; physical performance; and
quality of life. The scoring scale goes from 0 to 100: mild
cachexia (less than 25), moderate (more than 26 and less than
50),severe(morethan51andlessthan75),andterminalphase
(more than 76 and up to 100). The score also takes into
consideration the condition known as pre-cachexia.
Conclusion The presentscore willfacilitatecachexia staging
and will therefore allow for a more adequate therapy.
Keywords Cachexia.Wasting score.Anorexia.Weight
loss.Physical performance.Quality of life
1 Introduction: defining cachexia
Cachexia is a term originating from the Greek: “kakos” and
“hexis” meaning “bad condition”. The cachectic state is
observed in many pathological conditions such as cancer,
chronic obstructive pulmonary disease (COPD), sepsis, or
chronic heart failure. For several years, it has been considered
essential to develop a standardized definition of cachexia [1].
This represents a key issue for treatment, for reimbursement,
and for inclusion and exclusion from clinical trials. The
definition and diagnostic criteria must be clear on the
identification of the early signs. Also a key point, the
definition must include an appreciation that cachexia is found
in a number of life-limiting illnesses that the management of
this syndrome in end-of-life must be facilitated, albeit that
this is not done the same way as in earlier stages.
A group of international experts who met in Washington
DC (USA) in December 2006 for an international consensus
meeting organized by the Society for Cachexia and Wasting
Disorders stated: “cachexia is a complex metabolic syn-
drome associated with underlying illness and characterized
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prominent clinical feature of cachexia is weight loss in adults
(corrected for fluid retention) or growth failure in children
(excluding endocrine disorders). Anorexia, inflammation,
insulin resistance and increased muscle protein breakdown
are frequently associated with wasting disease. Wasting
disease is distinct from starvation, age-related loss of muscle
mass, primary depression, malabsorption and hyperthyroid-
ism and is associated with increased morbidity” [2].
Very recently, a consensus on this one and other
cachexia definitions [3, 4] has been reached and published.
The Consensus group reached two basic conclusions: (1)
there is a need to incorporate the term “pre-cachexia” as a
condition associated with no or very small weight loss (less
than 5% of body weight loss in 6 months) which is associated
with underlying chronic disease and characterized by anorex-
ia, inflammation, and/or metabolic alterations. Clearly, the
pre-cachectic population will be very heterogeneous, with
some patients progressing rapidly but others remaining
weight-stable. The development of suitable clinical identifiers
or biomarkers to map out the different cohorts will be an area
of intense interest; (2) some type of cachexia “staging” or
“score” is essential to be able to classify patients according to
the severity of the syndrome. The classification domains
(phenotyping) of patients could comprise of measures of
whole body and lean body mass loss, catabolic drivers
(including immune and inflammatory response), anorexia,
quality of life, and physical performance.
Bearing all this in mind, the object of the present study is
to fulfill the existing gap in the classification of cachectic
cancer patients by introducing a new score that takes into
consideration the stated parameters.
2 Diagnostic tools
In spite of the existence of different cachexia definitions
and consensus, cachexia is infrequently diagnosed. This is,
in part, due to the lack of clear standardized cachectic
markers. Some of the criteria used in the past include
weight loss, decreased physical performance, fatigue,
anorexia, and metabolic alterations. The group of inves-
tigators who met in Washington [2] concluded that cachexia
can be diagnosed in the following way: a weight loss of at
least 5% or more in 12 months or less in the presence of
underlying illness, plus three of the following criteria:
decreased muscle strength, fatigue, anorexia, low fat-free
mass index, abnormal biochemistry (increased inflammatory
markers (C-reactive protein >5.0 mg/l), IL-6 >4.0 pg/ml),
anemia (<12 g/dl), and low serum albumin (<3.2 g/dl)) [2].
However, other diagnostic tools should not be discarded,
such as decreased physical performance (total activity,
handgrip strength, stairs climb, or 6-min walk distance) or
biochemical tissue analysis (activation of proteolysis or
apoptosis in skeletal muscle biopsies [5]).
3 Staging cachexia: the cachexia score
As already stated above, in addition to clear and objective
diagnostic criteria, an essential requirement for both clinical
trials and patient treatment is a staging system that allows
for classification of the cancer patients according to the
severity of the cachectic syndrome. Such a staging system
would be beneficial not only for assessing the severity of
the syndrome but also to decide the type of treatment. It
was the aim of the present study to develop such a
classification system. The result is the newborn cachexia
score (CASCO) which, by means of a numerical scale,
classifies cachexia into mild (0–25), moderate (26–50),
severe (51–75), and terminal (76–100). It is therefore clear
that the higher the score, the worst the syndrome (Table 1).
4 Components
The main components of CASCO are: body weight loss
and composition, inflammation/metabolic disturbances/
Table 1 CASCO staging scale
cachexia score (CASCO): 
BWC (0-40) + IMD (0-20) + PHP (0-15) + ANO  (0-15) + QOL (0-10)
mild moderate severe
score        0                25                  50                    75                 100 
terminal phase 
BWC body weight loss and composition, IMD inflammation/metabolic disturbances/immunosupression, PHP physical performance, ANO
anorexia, QOL quality of life
88 J Cachexia Sarcopenia Muscle (2011) 2:87–93immunosupression, physical performance, anorexia, and
quality of life.
Indeed, body weight loss and composition is an essential
component of all definitions of cachexia. It is by far the
most important requirement, in addition to the presence of
an underlying disease such as cancer, COPD, chronic
infection. However, and due to the fact that both loss of
muscle and fat tissue coexist in the cachectic patient, it is
also important to assess any changes that may occur in
relation with lean body mass. From this point of view, a
decrease in lean body mass in the cachectic patient
represents impaired physical performance and therefore
quality of life, weight changes may just give an idea of
survival. Indeed, some authors claim that fat is associated
with survival while skeletal muscle is associated with loss
of quality of life [6]. In the CASCO, lean body mass
modulates the importance of body weight loss (Table 2).
Body weight loss and composition accounts for up 40% of
the cachexia score (Table 2).
The second component of CASCO is inflammation/
metabolic disturbances/immunosupression (IMD). Indeed,
inflammation is a very important component of the
cachectic response. Studies in pancreatic cancer patients
[7] clearly demonstrate an inflammatory response charac-
Table 2 The CACHEXIA score (CASCO): a new tool for staging cachectic patients
Symptom Percent Measurement Total points Parameter Values
BWC body weight loss and composition, IMD inflammation/metabolic disturbances/immunosupression, PHP physical performance, ANO
anorexia, QoL quality of life
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BWC 40 Body weight loss 32 <5%
≥5%, mild
≥10%, moderate
≥15%, severe
≥20%, terminal
Lean body mass 8 No change in LBM
Loss of LBM >10%
IMD 20 Inflammation 8 Plasma CRP 5 mg/l ≤CRP ≤10 mg/l
10 mg/l <CRP ≤20 mg/l
CRP >20 mg/l
Plasma IL6 4 pg/ml ≤IL6 ≤10 pg/ml
10 pg/ml <IL6 ≤30 pg/ml
IL6 >30 pg/ml
Metabolic disturbances 8 Plasma albumin <3.2 g/dL
Plasma pre-albumin <16 mg/dL
Plasma lactate >2.2 mM
Severe
Plasma triglycerides >200 mg/dL
Anemia Hb <12 g/dL
Plasma urea >50 mg/dL
Oxidative stress: ROS plasma levels >300 FORT U
Glucose tolerance test or HOMA index Altered
Immunosupression 4 IL2 levels >500 pg/ml
Peripheral lymphocytes: proliferation
assay or skin hypersensitivity test
Positive
PHP 15 15 Total activity Physical performance,
questionnaire, or monitoring Handgrip strength
Stairs climb
6-min walk distance
ANO 15 15 Simplified Nutrition Assessment
Questionnaire
Yes
QoL 10 10 Quality of life Questionnaire Mild
Moderateterized by increased levels of acute phase proteins (such as
C-reactive protein (CRP)) and cytokines (such as IL-6).
Other studies involving cachexia in pathological conditions
other than cancer [8] also suggest the importance of the
inflammatory response. The inflammatory component
accounts for up to 40% of IMD in CASCO. In addition to
inflammation, there are a number of metabolic disturbances
that are present in most of the cachectic patients; such
disturbances include glucose intolerance, anemia, and low
levels of plasmatic albumin, among others. Metabolic
disturbance component accounts for up to 40% of IMD in
CASCO. Finally, immunosupression might be an early
marker of cachexia [9]; therefore, assessment of the
immune response could also be a good indicator for a
cachexia staging system. The immunosupression compo-
nent accounts for up to 20% of IMD in CASCO. IMD
accounts for up 20% of the cachexia score (Table 2).
The third component relates to physical performance.
Indeed, even if there is a relative small decrease in muscle
mass due the cachectic syndrome, there may be a
significant decrease in physical-related activities which are
related to muscle performance [10, 11]. Therefore, assess-
ing physical performance is an essential component of any
cachectic staging system. Physical performance accounts
for up 15% of the cachexia score (Table 2).
Anorexia constitutes the fourth parameter included in
CASCO. Indeed, anorexia is an important component of
cachexia of many types of diseases [12]. A decrease in food
intake, by itself, promotes changes in quality of life and
also conditions with many metabolic alterations. Anorexia
accounts for up 15% of the cachexia score (Table 2).
Finally, the last component of CASCO is quality of life.
Indeed, quality of life reflexes are not just changes in
weight and physical performance but also in metabolic
alterations [11, 13]. It is therefore essential to take it into
consideration here. Quality of life accounts for up 10% of
the cachexia score (Table 2).
It is clear that the five different factors mentioned clearly
interact with one another and represent the most important
set of variables that might indicate the severity of cachectic
syndrome.
5 Methodology
The CASCO includes a comprehensive number of measure-
ments. All of these can be carried out either with physical or
biochemical tests together with the relevant questionnaires to
be filled by the patients with or without sanitary assistance.
In addition to weight determination, lean body mass can
be measured using either bioelectrical impedance analysis
(BIA) [14, 15] or dual X-ray absorptiometry (DEXA) [15,
16], although the latter is preferred [17].
Concerning inflammation, both CRP and IL-6 are easily
measured clinical parameters. The same applies for albu-
min, pre-albumin, lactate, triglycerides, hemoglobin, and
urea. Decreases in plasma albumin have been related with
the severity and the prognosis of different cachectic states
[18]. Pre-albumin is a good indicator of nutritional status
[18]. Elevations in plasma triglycerides are a common trend
in catabolic conditions related with cachexia [19]. In the
case of lactate, elevations in this marker are very frequent in
cancer patients but also indicative of the acidosis present in
other types of catabolic states [19]. Concerning hemoglo-
bin, anemia is often a condition associated with cachexia,
particularly in cancer [11]. Plasma urea, to some extent,
reflects nitrogen catabolism [20] and is therefore included
in the list. More time-consuming is the determination of
glucose tolerance; however, this can be replaced by assessing
the Homeostasis Model Assessment (HOMA index) [21],
and finally, and to some extent, though not a normal clinical
routine, is the determination of reactive oxygen species
(ROS) plasma levels. Oxidative stress is clearly associated
with cachexia, particularly in cancer [22, 23]. It is for this
reason that we have included a simple method for the
determination of plasma levels of ROS [24, 25]. In order to
estimate immunosupression, IL-2 levels will be determined.
This cytokine is known to be a clear activator of different T
cells [26]. In addition to the cytokine measurement, a
peripheral lymphocyte proliferation assay will be undertaken
[27] since this is a very indicative measurement of immune
Table 3 Physical performance
Physical performance staging of a cachectic patient
Questionnaire (during the past week)
a
Have you noticed any particular decrease in the physical activities
(i.e., at work, at home, at leisure, etc.…) that you normally
carry out during the day?
Have you had any problems doing strenuous activities, like carrying a
heavy shopping bag or a suitcase?
Have you noticed any loss of handgrip force?
Did you have to put more effort on climbing stairs?
Have you felt tired after walking approximately half a kilometer?
Monitoring
b
&Total physical activity
&Grip force
&Stair-climb
&6-min walk distance
aAdapted from EORTC QLQ-C30 (version 3) ©Copyright 1995
EORTC Study Group on Quality of Life
bMonitoring will take place at the same moment as the questionnaire
is filled, normally at the time of diagnose. The very first calculation of
the CACHEXIA SCORE will use the values from the questionnaire.
Subsequent calculations will use the monitored values of the items
under “Monitoring”
90 J Cachexia Sarcopenia Muscle (2011) 2:87–93response. Finally, skin hypersensitivity will also be deter-
mined with the relevant test [28]. These three measurements
give a clear indication of the immunologic response of the
patient. This is particularly important since a previously
stated immunosuppression may appear before any weight
loss takes place [9].
Concerning physical performance, standard measure-
ments for total activity [29], handgrip strength [30],
stairs climb [31] ,o r6 - m i nw a l kd i s t a n c e[ 32, 33] will be
undertaken (Tables 2 and 3). We have to take into
consideration the fact that monitoring will only be
possible after diagnosis; therefore, we have included a
physical performance questionnaire which will be used
at the moment of diagnosis in order to be able to use
this parameter in the staging of the cachectic patient
(Table 3, “Questionnaire”).
Anorexia will be estimated using a standard question-
naire (Simplified Nutrition Assessment Questionnaire
(SNAQ); Table 4).
Concerning quality of life, the questionnaire is presented
in Table 5. It has been adapted from EORTC QLQ-C30
[34], where questions related to physical performance or
food intake have been withdrawn.
Table 4 Anorexia questionnaire
Simplified Nutrition Assessment Questionnaire (SNAQ)
a
My appetite is
a. Very poor
b. Poor
c. Average
d. Good
e. Very good
When I eat
a. I feel full after eating only a few mouthfuls
b. I feel full after eating about a third of a meal
c. I feel full after eating over half a meal
d. I feel full after eating most of the meal
e. I hardly ever feel full
Food tastes
a. Very bad
b. Bad
c. Average
d. Good
e. Very good
Normally I eat
a. Less than one meal a day
b. One meal a day
c. Two meals a day
d. Three meals a day
e. More than three meals a day
aPointsare assignedforthepatient’s answers asfollows:a=1,b=2,c=3,
d=4, e=5. The sum of the scores for the individual items constitutes the
SNAQ score
Table 5 Quality of life questionnaire
During the past week
Do you need to stay in bed or a chair during the day?
Do you need help with eating, dressing, washing yourself, or using
the toilet?
Were you limited in doing either your work or other daily activities?
Were you limited in pursuing your hobbies or other leisure time
activities?
Were you short of breath?
Have you had pain?
Did you need to rest?
Have you had trouble sleeping?
Have you felt weak?
Have you felt nauseated?
Have you vomited?
Have you been constipated?
Have you had diarrhea?
Did pain interfere with your daily activities?
Have you had difficulty in concentrating on things, like reading a
newspaper or watching television?
Did you feel tense?
Did you worry?
Did you feel irritable?
Did you feel depressed?
Have you had difficulty remembering things?
Has your physical condition or medical treatment interfered with your
family life?
Has your physical condition or medical treatment interfered with your
social activities?
Has your physical condition or medical treatment caused you
financial difficulties?
How would you rate your overall health during the past week?
How would you rate your overall quality of life during the past week?
Adapted from EORTC QLQ-C30 (version 3) © Copyright 1995
EORTC Study Group on Quality of Life. First 23 questions: Not at all:
1; A little: 2; Quite a bit: 3; Very much: 4; Last two questions:
Excellent: 1, Fine: 2, Poor: 3, Very poor: 4
Table 6 Pre-cachexia
Quantitative approach
BWC=0
(IMD+PHP+QOL+ANO) >35
BWC body weight loss and composition, IMD inflammation/metabolic
disturbances/immunosupression, PHP physical performance, ANO
anorexia, QoL quality of life
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As we have previously mentioned in section 1, there may
be patients that, although they have not yet lost any
significant weight (less or equal to 5% in the last 12 months)
and are subjected to an underlying disease, which is often
associated with cachexia, may already have some of the
peculiarities associated with cachexia such as inflammation
or decreased physical performance. This condition has been
named as pre-cachexia [4]. However, no consensus on how
to classify the pre-cachectic patients has been reached in
spite of many suggestions [4]. It is for this reason that the
present publication also includes a tentative quantitative
approach for the diagnosis of pre-cachexia (Table 6). Pre-
cachexia would exist if the patient had at least 35 as the
sum of the different parameters that specifically exclude
body weight loss and composition; as we mentioned, it is
essential to have no significant weight loss for pre-cachexia
to exist (Table 6).
7 Validation and conclusions
Future efforts will concentrate on the validation of such a
staging system. Simple systems are generally preferable to
allow bedside assessments. The issue of validation is
difficult for such a score or staging system. There is a clear
need for high-quality international data, representative of
the disease populations. Cachexia researchers need to agree
and to gather a large prospective data set. Obviously,
interpretation of the data by appropriate statistical methods
is crucial. Correlation with patient prognosis may be useful,
but the relationship between score and outcome may be
different in different underlying diseases. Also, the rela-
tionship between score and treatment response to cachexia
interventions is a possible approach to validating such a
score. Although this may be the preferable approach, it
depends on availability of several treatment studies and
their having assessed all relevant parameters of interest. It
may be useful to generate a set of (simple) parameters that
all trials should assess in order to allow assessment of such
scores in the future and emphasize on the key importance of
similar developments in the definition of related terms like
sarcopenia, fatigue, and frailty. Although mainly intended
and designed for cancer patients, CASCO could also be
tentatively used for other wasting disorders such as chronic
heart failure or chronic obstructive pulmonary disease,
since many of both the biochemical and metabolic
alterations are similar. Obviously, this would have to be
validated.
In conclusion, a quantitative tentative (not yet validated)
staging score for cancer cachectic patients is presented. It is
already a tool for the (a) identification of pre-cachectic
patients, and (b) classification and staging of the syndrome
according to body weight loss and composition, inflamma-
tion/metabolic disturbances/immunosupression, physical
performance, anorexia, and quality of life. When validated,
the new CASCO might prove to be a useful tool for the
treatment and nutritional recommendations of cachectic
cancer patients in a similar way as other staging method-
ologies [35]. Future efforts will concentrate on a multicen-
ter clinical validation of the score.
8 Practical questionnaire and CASCO quantitation
procedure
The full CASCO calculation procedure and questionnaires can
be found in the following address: http://www.fbg.ub.es/index.
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